ArticleJournal of translational medicine2026
Clinical phenotypes across age groups and the predictive value of NT-proBNP for ventricular arrhythmias in left ventricular non-compaction: a multicenter cohort study.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical characteristics and short-term outcomes of left ventricular non-compaction cardiomyopathy in neonates.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo investigate the differences in clinical phenotypes between children and adult patient groups with left ventricular non-compaction (LVNC) and to evaluate the predictive efficacy of various biomarkers for ventricular arrhythmias (VAs) in LVNC.
methodsThis study included 408 patients diagnosed with LVNC by cardiac magnetic resonance (CMR) between 2016 and 2023 (Children group < 18 years, n = 135; Adult group ≥ 18 years, n = 273). Baseline data, imaging parameters, and biomarkers were collected. Multivariable logistic regression analysis was used to identify independent predictors of VAs in LVNC. The optimal cut-off value for NT-proBNP was determined using receiver-operating characteristic (ROC) curve analysis. A restricted cubic spline model was constructed to analyze the dose-response relationship. Finally, VAs risk was assessed using tertile stratification and subgroup analysis.
resultsCompared with the children group, the adult group showed significantly reduced cardiac function (LVEF-CMR 40.72% vs. 46.59%, P = 0.001), larger left ventricular end-diastolic diameter (TTE 59.23 mm vs. 51.43 mm, P < 0.001), and higher prevalence of chest pain (56.8% vs. 41.5%) and dyspnea (49.8% vs. 24.4%). The children group had a higher proportion of congenital heart disease than the adult group (21.5% vs. 5.9%, P < 0.001). Cardiac function and structure (LVEF, LVEDD, LAD) progressively worsened with increasing age. Worsening was more severe in patients comorbid with dilated cardiomyopathy, moderate/massive mitral regurgitation, and pulmonary hypertension. NT-proBNP was an independent predictor of VAs in LVNC (OR = 1.380, 95% CI: 1.062–1.794, P = 0.016). The area under the ROC curve was 0.72, with an optimal cut-off value of 576 pg/ml (Sensitivity 65.2%, Specificity 71.6%). When NT-proBNP > 1029 pg/ml (Tertile 3, T3), the risk of VAs was 3.09 times that of the T1 group (95% CI: 1.034–9.257). This risk remained significantly increased even in the subgroup with LVEF > 50% (OR = 2.16). Subgroup analysis revealed no interaction effects.
conclusionLVNC exhibits significant age-related heterogeneity, characterized predominantly by congenital abnormalities in childhood and by impaired cardiac function in adulthood. NT-proBNP serves as a strong predictive marker for VAs in LVNC. A risk stratification pathway based on thresholds of 576 pg/ml (screening threshold) and 1029 pg/ml (intervention node) shows promise for optimizing clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.